JPWO2020221274A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020221274A5 JPWO2020221274A5 JP2021564189A JP2021564189A JPWO2020221274A5 JP WO2020221274 A5 JPWO2020221274 A5 JP WO2020221274A5 JP 2021564189 A JP2021564189 A JP 2021564189A JP 2021564189 A JP2021564189 A JP 2021564189A JP WO2020221274 A5 JPWO2020221274 A5 JP WO2020221274A5
- Authority
- JP
- Japan
- Prior art keywords
- days
- body weight
- cough
- saturated
- partially unsaturated
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 230000037396 body weight Effects 0.000 claims 64
- 206010011224 Cough Diseases 0.000 claims 22
- 150000001875 compounds Chemical class 0.000 claims 17
- 229920006395 saturated elastomer Polymers 0.000 claims 14
- 125000000217 alkyl group Chemical group 0.000 claims 12
- 125000003710 aryl alkyl group Chemical group 0.000 claims 9
- 125000003118 aryl group Chemical group 0.000 claims 9
- 239000008194 pharmaceutical composition Substances 0.000 claims 9
- 125000006708 (C5-C14) heteroaryl group Chemical group 0.000 claims 7
- 150000001204 N-oxides Chemical class 0.000 claims 7
- 150000002148 esters Chemical class 0.000 claims 7
- 239000002207 metabolite Substances 0.000 claims 7
- 239000000651 prodrug Substances 0.000 claims 7
- 229940002612 prodrug Drugs 0.000 claims 7
- 150000003839 salts Chemical class 0.000 claims 7
- 239000012453 solvate Substances 0.000 claims 7
- 125000006714 (C3-C10) heterocyclyl group Chemical group 0.000 claims 6
- 208000013116 chronic cough Diseases 0.000 claims 6
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims 5
- 229910052736 halogen Inorganic materials 0.000 claims 5
- 150000002367 halogens Chemical class 0.000 claims 5
- 125000000623 heterocyclic group Chemical group 0.000 claims 5
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 4
- 125000004093 cyano group Chemical group *C#N 0.000 claims 4
- -1 cyclic hydrocarbyls Chemical group 0.000 claims 3
- 125000001072 heteroaryl group Chemical group 0.000 claims 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 3
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 3
- 125000004043 oxo group Chemical group O=* 0.000 claims 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 3
- 125000001424 substituent group Chemical group 0.000 claims 3
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims 2
- 238000009472 formulation Methods 0.000 claims 2
- 208000021302 gastroesophageal reflux disease Diseases 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 208000005069 pulmonary fibrosis Diseases 0.000 claims 2
- 229910052717 sulfur Inorganic materials 0.000 claims 2
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 1
- 206010020751 Hypersensitivity Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 206010057190 Respiratory tract infections Diseases 0.000 claims 1
- 206010070488 Upper-airway cough syndrome Diseases 0.000 claims 1
- 230000001154 acute effect Effects 0.000 claims 1
- 125000003342 alkenyl group Chemical group 0.000 claims 1
- 125000002947 alkylene group Chemical group 0.000 claims 1
- 125000000304 alkynyl group Chemical group 0.000 claims 1
- 208000026935 allergic disease Diseases 0.000 claims 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 claims 1
- 239000007900 aqueous suspension Substances 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 229910052794 bromium Inorganic materials 0.000 claims 1
- 239000002775 capsule Substances 0.000 claims 1
- 229910052801 chlorine Inorganic materials 0.000 claims 1
- 235000009508 confectionery Nutrition 0.000 claims 1
- 239000006071 cream Substances 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 239000002552 dosage form Substances 0.000 claims 1
- 239000000839 emulsion Substances 0.000 claims 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 claims 1
- 229910052731 fluorine Inorganic materials 0.000 claims 1
- 239000000499 gel Substances 0.000 claims 1
- 230000009610 hypersensitivity Effects 0.000 claims 1
- 230000000642 iatrogenic effect Effects 0.000 claims 1
- 230000002757 inflammatory effect Effects 0.000 claims 1
- 238000002347 injection Methods 0.000 claims 1
- 239000007924 injection Substances 0.000 claims 1
- 238000001361 intraarterial administration Methods 0.000 claims 1
- 238000010255 intramuscular injection Methods 0.000 claims 1
- 239000007927 intramuscular injection Substances 0.000 claims 1
- 238000007912 intraperitoneal administration Methods 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 229910052740 iodine Inorganic materials 0.000 claims 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 1
- 239000006210 lotion Substances 0.000 claims 1
- 239000007937 lozenge Substances 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 201000009240 nasopharyngitis Diseases 0.000 claims 1
- 230000001537 neural effect Effects 0.000 claims 1
- 239000002674 ointment Substances 0.000 claims 1
- 229910052760 oxygen Inorganic materials 0.000 claims 1
- 239000006072 paste Substances 0.000 claims 1
- 239000000843 powder Substances 0.000 claims 1
- 208000020029 respiratory tract infectious disease Diseases 0.000 claims 1
- 230000000391 smoking effect Effects 0.000 claims 1
- 239000000243 solution Substances 0.000 claims 1
- 239000007921 spray Substances 0.000 claims 1
- 238000007920 subcutaneous administration Methods 0.000 claims 1
- 239000000829 suppository Substances 0.000 claims 1
- 239000006188 syrup Substances 0.000 claims 1
- 235000020357 syrup Nutrition 0.000 claims 1
- 239000003826 tablet Substances 0.000 claims 1
- 230000000699 topical effect Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNPCT/CN2019/085180 | 2019-04-30 | ||
| CN2019085180 | 2019-04-30 | ||
| PCT/CN2020/087686 WO2020221274A1 (zh) | 2019-04-30 | 2020-04-29 | 二氨基嘧啶类化合物治疗咳嗽的方法 |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2022530890A JP2022530890A (ja) | 2022-07-04 |
| JPWO2020221274A5 true JPWO2020221274A5 (https=) | 2023-05-11 |
| JP2022530890A5 JP2022530890A5 (https=) | 2023-05-11 |
| JP7665529B2 JP7665529B2 (ja) | 2025-04-21 |
Family
ID=73029672
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021564189A Active JP7665529B2 (ja) | 2019-04-30 | 2020-04-29 | ジアミノピリミジン化合物を使用することによって咳を治療する方法 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20220211703A1 (https=) |
| EP (1) | EP3960179B1 (https=) |
| JP (1) | JP7665529B2 (https=) |
| KR (1) | KR102935436B1 (https=) |
| CN (1) | CN114007619B (https=) |
| AU (1) | AU2020265327B2 (https=) |
| BR (1) | BR112021021600A2 (https=) |
| MX (1) | MX2021013338A (https=) |
| SG (1) | SG11202111877TA (https=) |
| TW (1) | TWI736243B (https=) |
| WO (1) | WO2020221274A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7207634B2 (ja) | 2017-11-01 | 2023-01-18 | ベイジン タイド ファーマシューティカル カンパニー リミテッド | Ｐ２ｘ３及び／又はｐ２ｘ２／３受容体アンタゴニスト、それを含む医薬組成物及びその使用 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1930135B (zh) * | 2004-03-05 | 2011-12-28 | 弗·哈夫曼-拉罗切有限公司 | 作为p2x3和p2x2/3拮抗剂的二氨基嘧啶 |
| CA2619919C (en) * | 2005-09-01 | 2014-04-01 | F. Hoffmann-La Roche Ag | Diaminopyrimidines as p2x3 and p2x2/3 modulators |
| AU2007304280B2 (en) | 2006-10-04 | 2013-01-31 | F. Hoffmann-La Roche Ag | Process for synthesis of phenoxy diaminopyrimidine derivatives |
| RU2650118C2 (ru) * | 2013-08-23 | 2018-04-09 | Афферент Фармасьютикалз Инк. | Способ лечения острого, хронического и подострого кашля и непреодолимого желания откашляться |
| KR20180054843A (ko) * | 2015-09-29 | 2018-05-24 | 애퍼런트 파마슈티컬스 인크. | 기침 치료에 사용하기 위한 디아미노피리미딘 p2x3 및 p2x2/3 수용체 조정제 |
| MA43821A (fr) * | 2016-03-14 | 2018-11-28 | Afferent Pharmaceuticals Inc | Pyrimidines et variantes de celles-ci, et leurs utilisations |
| MA44489A (fr) * | 2016-03-25 | 2019-01-30 | Afferent Pharmaceuticals Inc | Pyrimidines et variants de celles-ci, et leurs utilisations |
| JP7207634B2 (ja) | 2017-11-01 | 2023-01-18 | ベイジン タイド ファーマシューティカル カンパニー リミテッド | Ｐ２ｘ３及び／又はｐ２ｘ２／３受容体アンタゴニスト、それを含む医薬組成物及びその使用 |
-
2020
- 2020-04-29 EP EP20799419.5A patent/EP3960179B1/en active Active
- 2020-04-29 JP JP2021564189A patent/JP7665529B2/ja active Active
- 2020-04-29 SG SG11202111877TA patent/SG11202111877TA/en unknown
- 2020-04-29 WO PCT/CN2020/087686 patent/WO2020221274A1/zh not_active Ceased
- 2020-04-29 CN CN202080032489.4A patent/CN114007619B/zh active Active
- 2020-04-29 BR BR112021021600A patent/BR112021021600A2/pt unknown
- 2020-04-29 US US17/607,438 patent/US20220211703A1/en active Pending
- 2020-04-29 MX MX2021013338A patent/MX2021013338A/es unknown
- 2020-04-29 AU AU2020265327A patent/AU2020265327B2/en active Active
- 2020-04-29 KR KR1020217038551A patent/KR102935436B1/ko active Active
- 2020-04-30 TW TW109114696A patent/TWI736243B/zh active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6745726B2 (ja) | 中枢神経系障害の処置における２，４−チアゾリジンジオン誘導体 | |
| KR102618119B1 (ko) | 말의 기도 질환의 치료를 위한 무스카린 길항제 및 이의 병용물 | |
| CN115190815A (zh) | 芳基环己基胺衍生物及其在精神障碍的治疗中的用途 | |
| CA3131137C (en) | Methods of treatment of respiratory disorders | |
| JP2022169636A (ja) | 肺高血圧症の治療のための併用療法 | |
| EP2080523A1 (en) | Compositions comprising an antimuscarinic and a long-acting beta-agonist | |
| JPWO2020259528A5 (https=) | ||
| JPWO2020177587A5 (https=) | ||
| JPWO2020221274A5 (https=) | ||
| US20140120121A1 (en) | Medicinal treatment of atopic inflammatory diseases | |
| CN117425487A (zh) | 肽酰胺类化合物制备用于治疗瘙痒的药物中的用途 | |
| RU2007105582A (ru) | Агонисты рецепторов никотина и способы их применения для лечения воспалительных заболеваний | |
| EA009935B1 (ru) | Новая синергетическая комбинация, включающая рофлумиласт и формотерол | |
| JPWO2020221277A5 (https=) | ||
| US12409179B2 (en) | Pharmaceutical combination of pimozide and methotrexate and use thereof | |
| JP7665529B2 (ja) | ジアミノピリミジン化合物を使用することによって咳を治療する方法 | |
| JPWO2022017412A5 (https=) | ||
| US11197851B2 (en) | Methods of treatment of asthma and COPD | |
| CN120035442A (zh) | 治疗尘肺病的方法 | |
| JPWO2021007277A5 (https=) | ||
| JP2008502639A (ja) | 咳の処置のためのキナゾリン化合物 | |
| Maxwell et al. | Calcium Antagonists | |
| WO2005051345A1 (de) | Tirofiban zur inhalativen verabreichung zur therapie von erkrankungen, die durch thrombusbildung verursacht werden |